Abstract
Pharmacogenetic advances in cancer chemotherapy have the potential to predict clinical benefit to particular regimens. Platinum agents have shown to be effective in the treatment of gastric cancer. We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. SNPs of XPD-751, XRCC1-399 and GSTP1-105 in 62 gastric cancer patients were evaluated using the TaqMan 5′ nuclease assay. Genotypes were correlated to survival. The median overall survival time was 322 days (range: 56–2058 days). The median survival times for patients with Arg/Arg or Arg/Gln genotypes of XRCC1 gene were significantly longer than others (P=0.03). For 58 patients with ECOG PS (Eastern Cooperative Oncology Group performance status)≤2, more obvious significance was demonstrated (P=0.002). Patients with XRCC1-399 Gln/Gln genotype demonstrated a significant worse survival. No significant association was found between SNPs of XPD-751, GSTP1-105 and survival (P=0.125, 0.475, respectively). XRCC1 genotyping might make tailor chemotherapy possible for gastric cancer patients treated with oxaliplatin-based chemotherapy.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Parkin DM, Bray F, Ferlay J, Pisani P : Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108.
Sadighi S, Mohagheghi MA, Montazeri A, Sadighi Z : Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF). BMC Cancer 2006; 6: 274.
Sumpter K, Harper-Wynne C, Cunningham D et al: Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005; 92: 1976–1983.
Van Cutsem E, Moiseyenko VM, Tjulandin S et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991–4997.
Rosell R, Cecere F, Santarpia M, Reguart N, Taron M : Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol 2006; 6: 323–331.
Olaussen KA, Dunant A, Fouret P et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983–991.
Marsh S, McLeod HL : Cancer pharmacogenetics. Br J Cancer 2004; 90: 8–11.
Gurubhagavatula S, Liu G, Park S et al: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22: 2594–2601.
Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC : ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer 2005; 4: 18.
Hayes JD, Pulford DJ : The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445–600.
Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA : Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19: 275–280.
Brem R, Hall J : XRCC1 is required for DNA single-strand break repair in human cells. Nucleic Acids Res 2005; 33: 2512–2520.
Nazarkina ZK, Khodyreva SN, Marsin S, Lavrik OI, Radicella JP : XRCC1 interactions with base excision repair DNA intermediates. DNA Repair (Amst) 2007; 6: 254–264.
Savas S, Kim DY, Ahmad MF, Shariff M, Ozcelik H : Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev 2004; 13: 801–807.
Kiyohara C, Takayama K, Nakanishi Y : Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer 2006; 54: 267–283.
Stern MC, Siegmund KD, Conti DV, Corral R, Haile RW : XRCC1, XRCC3, and XPD polymorphisms as modifiers of the effect of smoking and alcohol on colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 2384–2390.
Huang WY, Chow WH, Rothman N et al: Selected DNA repair polymorphisms and gastric cancer in Poland. Carcinogenesis 2005; 26: 1354–1359.
Hirata H, Hinoda Y, Tanaka Y et al: Polymorphisms of DNA repair genes are risk factors for prostate cancer. Eur J Cancer 2007; 43: 231–237.
Suh KW, Kim JH, Kim do Y, Kim YB, Lee C, Choi S : Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann Surg Oncol 2006; 13: 1379–1385.
de las Penas R, Sanchez-Ronco M, Alberola V et al: Spanish Lung Cancer Group. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006; 17: 668–675.
Bewick MA, Conlon MS, Lafrenie RM : Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol 2006; 24: 5645–5651.
Wu X, Gu J, Wu TT et al: Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006; 4: 3789–3798.
Ruzzo A, Graziano F, Kawakami K et al: Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 2006; 24: 1883–1891.
Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ : A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61: 8654–8658.
Ryu JS, Hong YC, Han HS et al: Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004; 44: 311–316.
Isla D, Sarries C, Rosell R et al: Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004; 15: 1194–1203.
Stoehlmacher J, Park DJ, Zhang W et al: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91: 344–354.
Xing D, Tan W, Wei Q, Lin D : Polymorphisms of the DNA repair gene XPD and risk of lung cancer in a Chinese population. Lung Cancer 2002; 38: 123–129.
Yang G, Shu XO, Ruan ZX et al: Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 2005; 103: 52–58.
Goekkurt E, Hoehn S, Wolschke C et al: Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients. Br J Cancer 2006; 94: 281–286.
Stoehlmacher J, Park DJ, Zhang W et al: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94: 936–942.
Wang D, Lippard SJ : Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4: 307–320.
Nishiyama M, Yamamoto W, Park JS et al: Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999; 5: 2620–2628.
Zhan M, Liu X : Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP. Chin Med J (Engl) 1999; 112: 336–339.
Acknowledgements
This work is supported in part by Research of Health Department in Jiangsu Province (H200640), Medical Technology Development Foundation of Nanjing (ZKX05015) and Clinical Medical Center for Hepatobiliary Disease in Jiangsu Province.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, B., Wei, J., Zou, Z. et al. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 15, 1049–1053 (2007). https://doi.org/10.1038/sj.ejhg.5201884
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.ejhg.5201884
Keywords
This article is cited by
-
Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy
Tumor Biology (2016)
-
XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis
Tumor Biology (2014)
-
XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis
Cancer Chemotherapy and Pharmacology (2013)
-
DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy
Medical Oncology (2012)
-
Genetic Polymorphism of XRCC1 Correlated with Response to Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer
Pathology & Oncology Research (2012)
